Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

NCT01309126 is registered in ClinicalTrials.gov with HiberCell, Inc. as lead sponsor.

NCT NCT01309126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01309126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Lead sponsor
HiberCell, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2011
Completion date
February 28, 2017
Enrollment
217 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer